North American Metered Dose Inhaler Market

North American Metered Dose Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jul 2022 | Report Code: OMR2020338 | Category : Medical Devices | Delivery Format: /

North American metered dose inhaler market was $2.9 billion in 2018 and is anticipated to grow at a substantial rate of 2.2% during the forecast period. The major factors that are contributing significantly in the market growth include rising air pollution, growing geriatric population, and high healthcare expenditure. The US and Canada are the major economies of North America. The rising prevalence of chronic respiratory diseases, increasing geriatric population, and technological advancement are the major factors augmenting the growth of metered dose inhaler market in North America region. The increasing demand for inhaler due to increasing COPD and asthma patients in the US have endorsed the approval of cohesive reimbursement policies in the US, is further fueling the growth of the market. The US is the major market due to greater healthcare expenditure and higher prevalence rate of respiratory diseases.

The North American metered dose inhaler market is segmented on the basis of type, application, and end-user. Based on the type, preventive, reliever, and long acting bronchodilators inhaler are analyzed. Preventive metered dose inhaler segment led the global metered dose inhaler market in 2018. The preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in market include Budesonide and Fluticasone. Moreover, on the basis of application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed. 

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing metered dose inhaler to cater to a wide range of customers within the region and across the globe. The major players of the North American inhaler market include 3M Co., AstraZeneca PLC, Aradigm Corp., Adherium Ltd., GlaxoSmithKline PLC, Novartis AG, ResMed Corp. (Propeller Health), Teva Pharmaceuticals Industries Ltd. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. 

Research Methodology

The market study of the North American metered dose inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for metered dose inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. North American Metered Dose Inhaler Market Research and Analysis by Type

2. North American Metered Dose Inhaler Market Research and Analysis by Application

3. North American Metered Dose Inhaler Market Research and Analysis by End-User

The Report covers:

  • Comprehensive research methodology of the North American metered dose inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the North American metered dose inhaler market.
  • Insights about market determinants which are stimulating the North American metered dose inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

1.2.2. By Geography

2. Market Overview and Insights

2.1. Scope of the Report 

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. North American Metered Dose Inhaler Market by Type

5.1.1. Preventive 

5.1.2. Reliever 

5.1.3. Long Acting Bronchodilators 

5.2. North American Metered Dose Inhaler Market by Application

5.2.1. Asthma 

5.2.2. Chronic Obstructive Pulmonary Disease (COPD)

5.3. North American Metered Dose Inhaler Market by End-User

5.3.1. Homecare

5.3.2. Hospitals and Clinics

6. Regional Analysis

6.1. US 

6.2. Canada

7. Company Profiles

7.1. 3M Co.

7.2. Acorda Therapeutics, Inc.

7.3. Adamis Pharmaceuticals Corp.

7.4. Adherium Ltd.

7.5. Aradigm Corp.

7.6. AstraZeneca PLC

7.7. Boehringer Ingelheim International GmbH

7.8. Drive Devilbiss Healthcare LLC

7.9. GlaxoSmithKline PLC

7.10. Koninklijke Philips N.V.

7.11. Manta Devices LLC

7.12. Novartis AG

7.13. Omron Healthcare Inc.

7.14. ResMed Corp.

7.15. Pulmatrix Inc.

7.16. Savara, Inc.

7.17. Sunovion Pharmaceuticals

7.18. Teva Pharmaceuticals Industries Ltd.

1. NORTH AMERICAN METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

2. NORTH AMERICAN METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)

3. NORTH AMERICAN METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)

4. NORTH AMERICAN METERED DOSE INHALER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)


1. NORTH AMERICAN METERED DOSE INHALER MARKET SHARE BY TYPE, 2018 VS 2025 (%)

2. NORTH AMERICAN METERED DOSE INHALER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)

3. NORTH AMERICAN METERED DOSE INHALER MARKET SHARE BY END-USER, 2018 VS 2025 (%)

4. US METERED DOSE INHALER MARKET SIZE, 2018-2025 ($ MILLION)

5. CANADA METERED DOSE INHALER MARKET SIZE, 2018-2025 ($ MILLION)